Perspective

You have free access to this content

Of mice and (wo)men: Mouse models of breast cancer metastasis to bone

  1. Robert H Goldstein1,
  2. Robert A Weinberg2,
  3. Michael Rosenblatt1,3,*

Article first published online: 8 FEB 2010

DOI: 10.1002/jbmr.68

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 3, pages 431–436, March 2010

Additional Information

How to Cite

Goldstein, R. H., Weinberg, R. A. and Rosenblatt, M. (2010), Of mice and (wo)men: Mouse models of breast cancer metastasis to bone. J Bone Miner Res, 25: 431–436. doi: 10.1002/jbmr.68

Author Information

  1. 1

    Program in Genetics, Tufts University Sackler School of Biomedical Sciences, Boston, MA, USA

  2. 2

    Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA, USA

  3. 3

    Department of Physiology and Medicine, Tufts University School of Medicine, Boston, MA, USA

*(current address): Office of the Chief Medical Officer, Merck Co., Inc., Whitehouse Station, NJ 08889, USA.

Publication History

  1. Issue published online: 17 MAR 2010
  2. Article first published online: 8 FEB 2010
  3. Accepted manuscript online: 8 FEB 2010 12:00AM EST
  4. Manuscript Accepted: 3 FEB 2010
  5. Manuscript Received: 16 JAN 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (82K)

References

  • 1
    Jermal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10–30.
    Direct Link:
  • 2
    Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol. 2002; 25: S32–38.
  • 3
    Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584–593.
  • 4
    Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosophonates. Clin Breast Cancer. 2000; 1: 43–51.
  • 5
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350: 1655–1664.
  • 6
    Rubens RD. The nature of metastatic bone disease. In: RubensRD, FogelmanI, eds. Bone Metastases: Diagnosis and Treatment. London: Springer-Verlag; 1992: 1–10.
  • 7
    Parsons JT, Zetter B, Mohla S. Shifting paradigms in tumor metastasis: challenges and opportunities. Cancer Biol Ther. 2002; 1: 582–585.
  • 8
    Lelekakis M, Moseley JM, Martin TJ, et al. A Novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999; 17: 163–170.
  • 9
    Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995; 51995;5: 3551–3557.
  • 10
    Mbalaviel G, Dunsan CR, Sasaki A, William PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in experimental metastasis model. Cancer Res. 1996; 56: 4063–4070.
  • 11
    Kang Y, Siegel P, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3: 537–549.
  • 12
    Nemeth JA, Harb JF, Barroros U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999l; 59: 1987–1993.
  • 13
    Shtivelman E, Namikawa R. Species-specific metastasis of human tumor cells in the sever combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci USA. 1995; 92: 4661–4665.
  • 14
    Yonou H, Yokose T, Kamijo T, et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/sever combined immunodeficient mice engrafted with human lung and bone. Cancer Res. 2001; 61: 2177–2182.
  • 15
    Kuperwasser C, Dessain S, Bierbaum BE, et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005; 65: 6130–6138.
  • 16
    Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 2002; 52: 1399–1405.
  • 17
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2: 563–572.
  • 18
    Fidler IJ. The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev Cancer. 2003; 3: 453–458.
  • 19
    Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature. 2008; 8: 329–340.
  • 20
    Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci. 2000; 5: 75–81.
  • 21
    Rodan GA. The development and function of the skeleton and bone metastases. Cancer. 2003; 97: 726–732.
    Direct Link:
  • 22
    Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005; 328: 679–687.
  • 23
    Weber MH, Goltzman D, Kosternuik P, et al. Mechanisms of tumor metastasis to bone. Crit Rev Eukaryot Gene Expr. 2000; 10: 281–302.
  • 24
    Goltzman D. Osteolysis and cancer. J Clin Invest. 2001; 107: 1219–1220.
  • 25
    Bäuerie T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer. 2005; 115: 177–186.
    Direct Link:
  • 26
    Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003; 97: 834–839.
    Direct Link:
  • 27
    Sloan EK, Anderson RL. Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci. 2002; 59: 1491–1502.
  • 28
    Noti JD. Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase Cα. Int J Oncol. 2000; 17: 1237–1243.
  • 29
    Waltregny D, Bellahcéne A, de Leval X, Florkin B, Weidle U, Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res. 2000; 15: 834–843.
    Direct Link:
  • 30
    Ibrahim T, Leong I, Sanchez-Sweatman O, et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis. 2000; 18: 253–260.
  • 31
    Bellahcéne A, Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull Cancer. 1997; 84: 17–24.
  • 32
    Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2003; 103: 41–50.
  • 33
    Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Scie USA. 2005; 102: 1454–1459.
  • 34
    Barnes GL, Hebert KE, Kamal M, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastasis-associated osteolytic disease. Cancer Res. 2004; 64: 4506–4513.
  • 35
    Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem. 2005; 96: 484–489.
    Direct Link:
  • 36
    Hunt NC, Fjikawa Y, Sabokbar A, Itonaga I, Harris A, Athanasou NA. Cellular mechanisms of bone resorption in breast carcinoma. Br J Cancer. 2001; 85: 78–84.
  • 37
    Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000; 10: 159–178.
  • 38
    Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J. Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem. 2001; 276: 46661–46670.
  • 39
    Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000; 88: 2892–2898.
    Direct Link:
  • 40
    Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer. 1999; 6: 333–347.
  • 41
    Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer. 2000; 88: 2903–2908.
    Direct Link:
  • 42
    Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 2003; 97: 733–738.
    Direct Link:
  • 43
    Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789–799.
  • 44
    Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 1992; 89: 10578–10582.
  • 45
    Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003; 163: 2113–2126.
  • 46
    Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA. 1994; 91: 11236–11240.
  • 47
    Nielsen LL, Discafani CM, Gurnani M, Tyler RD. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res. 1991; 51: 3762–3767.
  • 48
    Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987; 49: 465–475.
  • 49
    Hüsemann Y, Klein CA. The analysis of metastasis in transgenic mouse models. Transgenic Res. 2009; 18: 1–5.
  • 50
    Yu Y, Okayasu R, Weil MM, et al. Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res. 2001; 61: 1820–1824.
  • 51
    Mori N, Yamate J, Umesako S, Hong DP, Okumoto M, Nakao R. Preferential induction of mammary tumors in p53 hemizygous BALB/c mice by fractionated irradiation of a sublethal dose of X-rays. J Radiat Res (Tokyo). 2003; 44: 249–254.
  • 52
    Backlund MG, Trasti SL, Backlund DC, Cressman VL, Godfrey V, Koller BH. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res. 2001; 61: 6577–6582.
  • 53
    Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invas Metastasis. 1983; 3: 22–31.
  • 54
    Eckhardt BL, Parker BS, van Laar RK, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res. 2005; 3: 1–13.
  • 55
    Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117: 927–939.
  • 56
    Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett. 2009; 123: 97–102.
  • 57
    Gabrilovic D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004; 4: 941–952.
  • 58
    Gallimore A, Godkin A. Regulatory T cells and tumour immunity: observations in mice and men. Immunology. 2008; 123: 157–163.
  • 59
    DeNardo DG, Coussens LM. Inflammation and breast cancer—balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007; 9: 212.
  • 60
    Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protcol Immunol. 2008; 20: 20.9.1–20.9.10.
  • 61
    Wang CY, Chang YW. A model for osseous metastasis of human breast cancer established by intrafemur injection of the MDA-MB-435 cells in nude mice. Anticancer Res. 1997; 17: 2471–2474.
  • 62
    Neuder M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterization and in vivo effects of ibandronate on tumour growth. Int J Cancer. 2003; 107: 468–477.
    Direct Link:
  • 63
    Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997; 99: 2509–2517.
  • 64
    Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001; 16: 2027–2034.
    Direct Link:
  • 65
    Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2008; 25: 119–129.
  • 66
    Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009; 15: 960–966.
  • 67
    Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990; 50: 717–721.
  • 68
    Li X, Wang J, An Z, et al. Optically imageable metastatic mouse model of human breast cancer. Clin Exp Metastasis. 2002; 9: 347–350.
  • 69
    Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drug. 1999; 17: 343–359.
  • 70
    Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 557–563.
  • 71
    Yang W, Lam P, Kitching R, et al. Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther. 2007; 6: 1289–1294.
  • 72
    Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res. 2007; 67: 10304–10308.
  • 73
    Kim HJ, Kim UJ, Vunjak-Novakovic G, Min BH, Kaplan DL. Influence of macroporous protein scaffolds on bone tissue engineering from bone marrow stem cells. Biomaterials. 2004; 26: 4442–4452.
  • 74
    Li C, Vepari C, Jin HJ, Kim HJ, Kaplan DL. Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials. 2006; 27: 3115–3124.
  • 75
    Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Scie USA. 2004; 101: 4966–4971.
View Full Article (HTML) Get PDF (82K)